Market Access of Biosimilars in the EU - Value Assessment/HTA?
30.09.2015 15:54
With experts from HAS, NICE, RADS Denmark, G-BA, CatSalut
Value assessment for biosimilars and the regulation of the substitution - these hot topics will be discussed at the meeting.
Termindetails
Wann
14.12.2015
von 18:00 bis 20:30
von 18:00 bis 20:30
Wo
Berlin
Kontakttelefon
+49 6221 500-680
Teilnehmer
This meeting addresses the needs of managing directors and co-workers in the pharmaceutical industry who are involved in market access and healthcare management of biosimilars.
Especially those who are responsible for the international business will benefit from this meeting.
Especially those who are responsible for the international business will benefit from this meeting.
Aims and objectives:
Biosimilars are playing an increasingly important role in the national healthcare systems of the EU. But market access and reimbursement are facing challenges:
- Is there a consensus regarding whether or not HTA assessment is necessary for biosimilars?
- How can a substitution be regulated and potentially also be enforced?
These and further topics will be addressed in an intensive discussion among experts from five national HTA bodies.
Topics:
- Market access for biosimilars in Germany - the current challenges and regulatory trends at a glance
- Market access for biosimilars in the UK, France, Germany, Spain/Catalonia and Denmark
- Current discussion: Value assessment for biosimilars foreseen? Substitution regulated?
